KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Change in Acquisitions & Divestments: 2009-2024

Historic Change in Acquisitions & Divestments for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Dec 2024 value amounting to $1.6 billion.

  • Alnylam Pharmaceuticals' Change in Acquisitions & Divestments rose 70.80% to $723.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year increase of 35.56%. This contributed to the annual value of $1.6 billion for FY2024, which is 1.15% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Change in Acquisitions & Divestments of $1.6 billion as of FY2024, which was up 1.15% from $1.6 billion recorded in FY2023.
  • Alnylam Pharmaceuticals' 5-year Change in Acquisitions & Divestments high stood at $2.2 billion for FY2022, and its period low was $1.5 billion during FY2021.
  • In the last 3 years, Alnylam Pharmaceuticals' Change in Acquisitions & Divestments had a median value of $1.6 billion in 2024 and averaged $1.8 billion.
  • In the last 5 years, Alnylam Pharmaceuticals' Change in Acquisitions & Divestments spiked by 52.48% in 2022 and then plummeted by 30.37% in 2023.
  • Yearly analysis of 5 years shows Alnylam Pharmaceuticals' Change in Acquisitions & Divestments stood at $1.7 billion in 2020, then dropped by 13.48% to $1.5 billion in 2021, then spiked by 52.48% to $2.2 billion in 2022, then crashed by 30.37% to $1.6 billion in 2023, then grew by 1.15% to $1.6 billion in 2024.